News | March 15, 2022
Granules Pharmaceuticals clears USFDA audit
This is the sixth successful USFDA audit for this facility
This is the sixth successful USFDA audit for this facility
Technology adoption helped the industry to sail through Covid-19 disruption as it understood the need to digitize, learn, and excel
The audit is a PAI for two of its product applications filed from this facility
Incidences of Non-alcoholic Fatty Liver Disease (NAFLD) have been rising exponentially worldwide and are associated with co-morbidities including obesity, diabetes, hypertension and metabolic disorders
The capsules are indicated for the maintenance of normal sinus rhythm in patients with atrial fibrillation/atrial flutter of greater than one week duration who have been converted to normal sinus rhythm
The US FDA has closed the observations pertaining to this audit with an Establishment Inspection Report on the 20th of July 2021
Subscribe To Our Newsletter & Stay Updated
